0% commission for ETF trades
NASDAQ:AFMD
Affimed N.V. Stock News
$4.00
+0.130 (+3.36%)
At Close: Sep 13, 2024
Affimed to Present at the Cantor Global Healthcare Conference 2024
06:30am, Tuesday, 10'th Sep 2024
MANNHEIM, Germany, Sept. 10, 2024 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD) (“Affimed”, or the “Company”), a clinical-stage immuno-oncology company committed to giving patients back thei
Affimed N.V. (AFMD) Q2 2024 Earnings Call Transcript
11:17am, Thursday, 05'th Sep 2024
Affimed N.V. (NASDAQ:AFMD ) Q2 2024 Earnings Conference Call September 5, 2024 8:30 AM ET Company Participants Alex Fudukidis - Head, Investor Relations Shawn Leland - Chief Executive Officer Andreas
Affimed Reports Second Quarter 2024 Financial Results & Business Update
06:30am, Thursday, 05'th Sep 2024
MANNHEIM, Germany, Sept. 05, 2024 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD) (“Affimed” or the “Company”), a clinical-stage immuno-oncology company committed to giving patients back their
Affimed Follow Up: Upcoming Acimtamig And AFM24 Updates Could Be Positive Catalysts
04:40pm, Wednesday, 04'th Sep 2024
On 06/11/24, I published an article on Affimed focused on my belief the company's upcoming acimtamig update would be positive. It was, and Affimed's stock popped the next day. The stock has since drop
Affimed Appoints New CEO, Shares Fall on Leadership Change
12:30pm, Wednesday, 04'th Sep 2024
AFMD appoints Shawn M. Leland as the company's new chief executive officer.
Affimed Appoints Shawn M. Leland as Chief Executive Officer
07:45am, Tuesday, 03'rd Sep 2024
MANNHEIM, Germany, Sept. 03, 2024 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD) (“Affimed” or the “Company”), a clinical-stage immuno-oncology company committed to giving patients back their
Affimed to Report Second Quarter 2024 Financial Results & Corporate Update on September 5, 2024
06:30am, Thursday, 29'th Aug 2024
MANNHEIM, Germany, Aug. 29, 2024 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, annou
Affimed N.V. (AFMD) Q1 2024 Earnings Call Transcript
10:48am, Wednesday, 12'th Jun 2024
Affimed N.V. (NASDAQ:AFMD ) Q1 2024 Earnings Conference Call June 12, 2024 8:30 AM ET Company Participants Alexander Fudukidis – Head, IR Andreas Harstrick – CMO and Interim CEO Michael Wolf – V
Affimed Reports First Quarter 2024 Financial Results & Business Update
06:30am, Wednesday, 12'th Jun 2024
- Initial data from the LuminICE-203 study shows 85.7% overall response rate (ORR) (6 of 7 patients); 4 out of 7 patients with complete response (CR) -
Affimed to Report First Quarter 2024 Financial Results & Corporate Update on June 12, 2024
06:30am, Wednesday, 05'th Jun 2024
MANNHEIM, Germany, June 05, 2024 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, annou
Affimed (AFMD) Soars on Upbeat Follow-Up Data From NSCLC Study
12:36pm, Tuesday, 04'th Jun 2024
Affimed (AFMD) rallies 69% on positive follow-up efficacy data from its early to mid-stage study of the AFM24/Tecentriq combo therapy to treat heavily-pretreated EGFR wild-type NSCLC patients.
Is Affimed (AFMD) Outperforming Other Medical Stocks This Year?
10:40am, Tuesday, 04'th Jun 2024
Here is how Affimed N.V. (AFMD) and Actinium Pharmaceuticals (ATNM) have performed compared to their sector so far this year.
MANNHEIM, Germany, June 01, 2024 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today
Affimed Receives Fast Track Designation for Combination Therapy of AFM24 with Atezolizumab for EGFR Wild-Type Non-Small Cell Lung Cancer
06:30am, Wednesday, 29'th May 2024
Efficacy and safety of AFM24 in combination with atezolizumab, a checkpoint inhibitor, is being evaluated in non-small cell lung cancer patients with EGFR wild-type and EGFR mutant advanced/metastatic
Affimed Announces Annual General Meeting of Shareholders
06:30am, Tuesday, 28'th May 2024
MANNHEIM, Germany, May 28, 2024 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD) (“Affimed”, or the “Company”), a clinical-stage immuno-oncology company committed to giving patients back their
